Related Experiment Video
Updated: Aug 14, 2026

An Oncogenic Hepatocyte-Induced Orthotopic Mouse Model of Hepatocellular Cancer Arising in the Setting of Hepatic Inflammation and Fibrosis
Published on: September 12, 2019
[Multiple hepatocellular carcinomas successfully treated by combined therapies]
Toshiya Ochiai1, Teruhisa Sonoyama, Shojiro Kikuchi
1Dept. of Surgery, Kyoto Prefectural University of Medicine.
Abstract:
We report a case of advanced multiple hepatocellular carcinomas (HCC), successfully treated by combination therapies of transarterial chemoembolization (TAE), operation and radiofrequency ablation therapy (RFA). A 59 year-old man was detected with an increased serum alpha-fetoprotein (AFP) level and an ultrasonography (US) revealed three nodules of HCC at the right lobe in August 1998. He was successfully treated with a combination therapy of TAE and percutaneous ethanol injection therapy (PEIT) at the beginning. However, HCC had recurred quite often. TAE had been repeated for twelve times before right trisegmentectomy was performed in November 2002. Thirteen months after the operation, CT revealed a new lesion at subsegment 3, which was treated by RFA. Furthermore, a metastatic single lesion had appeared at the left lung, which was resected. He has still been well for 82 months since the first detection of HCC.
Related Concept Videos
Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Targeted Cancer Therapies
There are several types of targeted therapies against specific...
Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Tumor Immunotherapy
